{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:34:10Z","timestamp":1784846050103,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clml.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:27:18Z","timestamp":1727717238000},"page":"e103-e109.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-3115","authenticated-orcid":false,"given":"T.","family":"Chalopin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-0658","authenticated-orcid":false,"given":"M.","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Decaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gounot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"A.","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Slama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-4614","authenticated-orcid":false,"given":"O.","family":"Allangba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zunic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Newinger-Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Botoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JV.","family":"Malfuson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garlantezec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.09.006_bib0001","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2018. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2018\/. Accessed: October 8, 2022."},{"issue":"24","key":"10.1016\/j.clml.2024.09.006_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.006_bib0003","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.09.006_bib0004","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9868","key":"10.1016\/j.clml.2024.09.006_bib0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.09.006_bib0006","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.09.006_bib0007","unstructured":"European Medicines Agency. Points to consider on frailty: evaluation instruments for baseline characterisation of clinical trial populations. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/12\/WC500199243.pdf. Accessed: October 8, 2022."},{"issue":"1","key":"10.1016\/j.clml.2024.09.006_bib0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.clml.2024.09.006_bib0008","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.006_bib0009","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.09.006_bib0010","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.09.006_bib0038","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jgo.2019.07.004","article-title":"A comparison of three different approaches to defining frailty in older patients with multiple myeloma","volume":"11","author":"Isaacs","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.006_bib0039","doi-asserted-by":"crossref","first-page":"215","DOI":"10.14283\/jfa.2019.25","article-title":"Comparison of frailty scores in newly diagnosed patients with multiple myeloma: a review","volume":"8","author":"Mian","year":"2019","journal-title":"J Frailty Aging"},{"key":"10.1016\/j.clml.2024.09.006_bib0011","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CCO.0000000000000792","article-title":"Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?","volume":"33","author":"M\u00f6ller","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.006_bib0012","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0013","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1002\/cam4.5234","article-title":"Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: a multicenter retrospective study in China","volume":"12","author":"Bao","year":"2023","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.clml.2024.09.006_bib0014","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jgo.2020.03.005","article-title":"The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma","volume":"11","author":"Fiala","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.09.006_bib0015","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.12659\/MSM.907588","article-title":"Real-world clinical outcomes in elderly Chinese patients with multiple myeloma: a single-center experience","volume":"23","author":"Qian","year":"2018","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.clml.2024.09.006_bib0036","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00277-021-04529-5","article-title":"Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma","volume":"100","author":"Cejalvo","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0016","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How I Treat Multiple myeloma in the geriatric patient","volume":"143","author":"Facon","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.09.006_bib0017","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00277-019-03640-y","article-title":"Multiple myeloma in elderly patients-a Portuguese multicentric real-life study","volume":"98","author":"Joao","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0018","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","article-title":"Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies","volume":"36","author":"Bal","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0037","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020 [published correction appears in Ann Oncol. 2022 Jan;33(1):117]","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.006_bib0019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejh.13530","article-title":"Survival trends in elderly myeloma patients","volume":"106","author":"Jones","year":"2021","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.09.006_bib0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-021-00524-1","article-title":"Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect\u00ae MM Registry","volume":"11","author":"Lee","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2024.09.006_bib0021","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.09.006_bib0022","doi-asserted-by":"crossref","unstructured":"Manier S. A dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial. Oral abstract #569. 64th American Society of Hematology Annual Meeting and Exposition, 2022; New Orleans, US.","DOI":"10.1182\/blood-2022-159933"},{"issue":"25","key":"10.1016\/j.clml.2024.09.006_bib0023","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.46989\/001c.121371","article-title":"The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge","volume":"6","author":"Decaux","year":"2024","journal-title":"Clin hematol Int"},{"issue":"1","key":"10.1016\/j.clml.2024.09.006_bib0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2015.1041386","article-title":"Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents","volume":"57","author":"Matsue","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.09.006_bib0026","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2012.01784.x","article-title":"Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era","volume":"89","author":"Dimopoulos","year":"2012","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4065\/mcp.2009.0426","article-title":"Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic","volume":"85","author":"Turesson","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.clml.2024.09.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101592","article-title":"Risk of cancer-specific death among octogenarians with multiple myeloma: a population-based analysis","volume":"14","author":"Britto","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"22","key":"10.1016\/j.clml.2024.09.006_bib0029","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.09.006_bib0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/CIA.S168687","article-title":"Current and emerging biomarkers of frailty in the elderly","volume":"14","author":"Saedi","year":"2019","journal-title":"Clin Interv Aging"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0031","doi-asserted-by":"crossref","first-page":"e13314","DOI":"10.1111\/acel.13314","article-title":"Senescent cells and the incidence of age-related diseases","volume":"20","author":"Katzir","year":"2021","journal-title":"Aging Cell"},{"issue":"12","key":"10.1016\/j.clml.2024.09.006_bib0032","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1080\/10428194.2021.1950708","article-title":"Treatment and outcome of newly diagnosed multiple myeloma patients >75 years old: a retrospective analysis","volume":"62","author":"Al Saleh","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2024.09.006_bib0033","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.006_bib0034","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.09.006_bib0035","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:59:30Z","timestamp":1738061970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2152265024023504"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}